The sodium‑glucose cotransporter 2 (SGLT2) is described in the source as a low‑affinity, high‑capacity transporter predominantly located in the renal proximal tubule. Its physiological role is to mediate the sodium‑coupled reabsorption of most filtered glucose. Pharmacologic blockade of SGLT2 therefore reduces proximal tubular glucose reabsorption and produces glycosuria.
Beyond glycosuria, inhibition of proximal tubular transport triggers an osmotic diuresis and restores tubuloglomerular feedback. These early renal effects contribute to resetting renal haemodynamics and to altered fluid compartmentalisation. The Review frames these changes as primary pharmacodynamic events that subsequently interact with systemic metabolic and cellular adaptations.
The source emphasizes that the renal and circulatory effects of SGLT2 inhibitors are coupled with systemic metabolic responses. Noted adaptations include signalling consistent with a pseudo‑starvation state, stimulation of erythropoiesis, altered handling of uric acid, and changes in substrate availability. These systemic responses are presented as part of the mechanism by which SGLT2 inhibitors exert broader effects beyond glycaemic lowering.
Together, the renal haemodynamic shifts, osmotic diuresis, and metabolic adaptations form an integrated pharmacodynamic profile that helps explain clinical benefits across multiple disease domains.
At the cellular level, SGLT2 inhibition has been linked to several intracellular and organelle‑level changes. The Review highlights associations with improved ionic homeostasis and enhanced mitochondrial quality control. Reduced oxidative stress and modulation of inflammatory responses are also described. These cellular effects are positioned as mechanisms that can attenuate maladaptive tissue remodelling in organs exposed to metabolic, haemodynamic, or inflammatory stress.
The source frames these cellular-level processes as mechanistic contributors to the observed organ‑level benefits, while noting that they integrate with vascular and stromal responses.
Endothelial injury is proposed in the Review as a potential link between cellular effects and microvascular dysfunction that can promote fibrosis. The authors discuss endothelial‑to‑mesenchymal transition (EndMT) as a mechanistic framework connecting microvascular injury with fibrotic remodelling. Importantly, EndMT is presented not as a single, proven mediator of clinical benefit but as one component of a broader endothelial–stromal stress response.
This conceptualization underscores that multiple interacting pathways—endothelial injury, inflammation, metabolic stress, and stromal activation—likely contribute to tissue remodelling and the downstream clinical outcomes that SGLT2 inhibitors modify.
The Review integrates pharmacodynamic and cellular evidence to account for the consistent efficacy of SGLT2 inhibitors across type 2 diabetes, chronic kidney disease (CKD), and heart failure (HF). The authors argue that the combination of renal haemodynamic effects, systemic metabolic shifts, and cellular protective mechanisms provides a unifying explanation for benefits observed across these conditions.
While the source does not detail specific trial outcomes in this abstract, it highlights the consistency of clinical efficacy across the cardio‑renal‑metabolic spectrum as a principal observation that the mechanistic data help to explain.
The Review identifies several areas where SGLT2 inhibitors are being evaluated beyond established indications. These include use in acute heart failure, administration after myocardial infarction, and potential roles in patients with arrhythmia or metabolic dysfunction‑associated steatohepatitis. The abstract frames these as emerging applications informed by the mechanistic and pharmacological profile of SGLT2 inhibition.
The source presents these extensions as areas of active translational interest rather than established standard indications in the abstract.
The authors highlight unresolved translational gaps and propose future directions intended to refine mechanistic understanding and improve precision use. Recommended priorities reported in the source include development of mechanism‑informed biomarkers, advanced imaging and spatial multi‑omics, phenotype‑guided patient stratification, exploration of dual SGLT1/2 inhibition, and investigation of rational combination therapy. These priorities are positioned as means to bridge mechanistic insights and clinical implementation.
This Review was published in Mol Biomed in 2026 (PMID 42814168; DOI 10.1186/s43556-026-00604-3). The authors declare no competing interests relevant to the content of the article, and the abstract indicates that ethics approval and consent to participate were not applicable. Keywords provided by the source include the cardio‑renal‑metabolic continuum, chronic kidney disease, EndMT, heart failure, precision medicine, and SGLT2 inhibitors.